Pharmacodynamic effect of nicardipine on left ventricular function in systemic sclerosis

• Published in: Journal of cardiovascular pharmacology Vol. 15; no. 2; p. 249
• Main Authors: Kahan, A, Devaux, J Y, Amor, B, Menkès, C J, Weber, S, Guérin, F, Venot, A, Strauch, G
• Format: Journal Article
• Language: English
• Published: United States 01-02-1990
• Subjects: Adult; Aged; Female; Heart - diagnostic imaging; Heart - drug effects; Heart - physiopathology; Heart Ventricles - drug effects; Heart Ventricles - physiopathology; Humans; Male; Middle Aged; Nicardipine - adverse effects; Nicardipine - therapeutic use; Radionuclide Ventriculography; Scleroderma, Systemic - diagnostic imaging; Scleroderma, Systemic - drug therapy; Scleroderma, Systemic - physiopathology
• ISSN: 0160-2446
• DOI: 10.1097/00005344-199002000-00011

Left ventricular dysfunction in systemic sclerosis may be due in part to myocardial ischemia caused by a disturbance in coronary microcirculation. We evaluated the pharmacodynamic effect of the calcium channel blocker nicardipine on left ventricular function assessed by radionuclide ventriculography in 20 patients with systemic sclerosis. Resting gated, blood-pool images were obtained at baseline and 90 min after 40 mg of oral nicardipine. The mean (+/- SEM) left ventricular ejection fraction significantly increased from 65.4 +/- 2.3% at baseline to 71.3 +/- 2.3% after nicardipine (p less than 0.005). The mean global defect score significantly decreased from 2.90 +/- 0.73 without nicardipine to 1.50 +/- 0.52 with nicardipine (p less than 0.01). The mean number of left ventricular sectors with severe hypokinesis significantly decreased from 0.80 +/- 0.24 at baseline to 0.20 +/- 0.09 after nicardipine (p less than 0.05). No significant side effects were observed with nicardipine. These results demonstrate short-term improvement in left ventricular function with nicardipine in patients with systemic sclerosis.